Eisenberger, Mario A <br/><br/>
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.  [electronic resource] 

 -  Urology  Jan 2004 
 - 114-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/j.urology.2003.08.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>5-alpha Reductase Inhibitors<br/>Adenocarcinoma--blood<br/>Androgen Antagonists--administration & dosage<br/>Androstenediols--blood<br/>Benzoquinones--administration & dosage<br/>Biomarkers, Tumor--blood<br/>Chemical and Drug Induced Liver Injury--etiology<br/>Dihydrotestosterone--blood<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--administration & dosage<br/>Estradiol--blood<br/>Humans<br/>Isoenzymes--antagonists & inhibitors<br/>Life Tables<br/>Male<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Orchiectomy<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Safety<br/>Substrate Specificity<br/>Testosterone--blood<br/>Treatment Outcome